AGL Stock Overview
A medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ANGLE plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.14 |
52 Week High | UK£0.37 |
52 Week Low | UK£0.091 |
Beta | 0.15 |
1 Month Change | -39.78% |
3 Month Change | -5.08% |
1 Year Change | -15.15% |
3 Year Change | -88.80% |
5 Year Change | -77.24% |
Change since IPO | -90.64% |
Recent News & Updates
Recent updates
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Mar 20Will ANGLE (LON:AGL) Spend Its Cash Wisely?
Dec 02We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Aug 11We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Feb 28ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Jul 16ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Aug 23We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate
May 02What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?
Feb 14We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Dec 22Shareholder Returns
AGL | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -6.7% | -1.9% | -1.5% |
1Y | -15.2% | -10.4% | 3.8% |
Return vs Industry: AGL underperformed the UK Medical Equipment industry which returned -9.6% over the past year.
Return vs Market: AGL underperformed the UK Market which returned 4.2% over the past year.
Price Volatility
AGL volatility | |
---|---|
AGL Average Weekly Movement | 18.0% |
Medical Equipment Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: AGL's share price has been volatile over the past 3 months.
Volatility Over Time: AGL's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 173 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer.
ANGLE plc Fundamentals Summary
AGL fundamental statistics | |
---|---|
Market cap | UK£44.66m |
Earnings (TTM) | -UK£20.13m |
Revenue (TTM) | UK£2.19m |
20.4x
P/S Ratio-2.2x
P/E RatioIs AGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGL income statement (TTM) | |
---|---|
Revenue | UK£2.19m |
Cost of Revenue | UK£658.00k |
Gross Profit | UK£1.53m |
Other Expenses | UK£21.66m |
Earnings | -UK£20.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jun 17, 2024
Earnings per share (EPS) | -0.063 |
Gross Margin | 69.90% |
Net Profit Margin | -920.95% |
Debt/Equity Ratio | 0% |
How did AGL perform over the long term?
See historical performance and comparison